Browsing by Author "McGuire, Darren K"
Now showing items 1-8 of 8
-
Effect of linagliptin versus placebo on cardiovascular and kidney outcomes in nephrotic-range proteinuria and type 2 diabetes: the CARMELINA randomized controlled trial.
(Clinical kidney journal, 2021-01-17)<h4>Background</h4>Nephrotic-range proteinuria (NRP) is associated with rapid kidney function loss and increased cardiovascular (CV) disease risk. We assessed the effects of linagliptin (LINA) on CV and kidney outcomes in ... -
Effects of Linagliptin on Cardiovascular and Kidney Outcomes in People With Normal and Reduced Kidney Function: Secondary Analysis of the CARMELINA Randomized Trial.
(Diabetes care, 2020-08)<h4>Objective</h4>Type 2 diabetes is a leading cause of kidney failure, but few outcome trials proactively enrolled individuals with chronic kidney disease (CKD). We performed secondary analyses of cardiovascular (CV) and ... -
Executive summary: heart disease and stroke statistics--2013 update: a report from the American Heart Association.
(Circulation, 2013-01)Each year, the American Heart Association (AHA), in conjunction with the Centers for Disease Control and Prevention, the National Institutes of Health, and other government agencies, brings together the most up-to-date statistics ... -
Executive summary: heart disease and stroke statistics--2014 update: a report from the American Heart Association.
(Circulation, 2014-01)Each year, the American Heart Association (AHA), in conjunction with the Centers for Disease Control and Prevention, the National Institutes of Health, and other government agencies, brings together the most up-to-date statistics ... -
Heart disease and stroke statistics--2013 update: a report from the American Heart Association.
(Circulation, 2013-01)Each year, the American Heart Association (AHA), in conjunction with the Centers for Disease Control and Prevention, the National Institutes of Health, and other government agencies, brings together the most up-to-date statistics ... -
Heart disease and stroke statistics--2014 update: a report from the American Heart Association.
(Circulation, 2014-01)Each year, the American Heart Association (AHA), in conjunction with the Centers for Disease Control and Prevention, the National Institutes of Health, and other government agencies, brings together the most up-to-date statistics ... -
Heart disease and stroke statistics--2015 update: a report from the American Heart Association.
(Circulation, 2015-01)Each year, the American Heart Association (AHA), in conjunction with the Centers for Disease Control and Prevention, the National Institutes of Health, and other government agencies, brings together the most up-to-date statistics ... -
Rationale, design, and baseline characteristics of the CArdiovascular safety and Renal Microvascular outcomE study with LINAgliptin (CARMELINA®): a randomized, double-blind, placebo-controlled clinical trial in patients with type 2 diabetes and high cardio-renal risk.
(Cardiovascular diabetology, 2018-03-14)BACKGROUND:Cardiovascular (CV) outcome trials in type 2 diabetes (T2D) have underrepresented patients with chronic kidney disease (CKD), leading to uncertainty regarding their kidney efficacy and safety. The CARMELINA® trial ...
